中国中药杂志2026，Vol.51Issue(14)：3939-3946,8.DOI:10.19540/j.cnki.cjcmm.20260403.501
中医药调控SREBP通路防治高脂血症研究进展
Research advance on regulation of SREBP pathway by TCM in prevention and treatment of hyperlipidemia
摘要
Abstract
Hyperlipidemia(HLP)is a significant independent risk factor for the occurrence and development of cardiovascular and cerebrovascular diseases.Currently,the common clinical lipid-lowering agents include statins(inhibiting HMG-CoA reductase),fibrates(activating PPARα),cholesterol absorption inhibitors(blocking NPC1L1),and PCSK9 inhibitors(preventing LDLR degradation).However,clinical concerns remain about the combination use of multiple drugs,hepatorenal toxicity,and poor adherence to long-term application.The sterol regulatory element-binding protein(SREBP)pathway serves as a master regulator of lipid synthesis,concurrently controlling multiple steps in this process.Targeted intervention of the overactivated SREBP pathway has emerged as a novel research direction for regulating lipid metabolism disturbances,though it remains largely in the preclinical stage of drug research and development.TCM demonstrates multi-target and holistic regulatory advantages in regulating the SREBP pathway.Studies reveal that TCM compounds(Zexie Decoction,Xiangsha Liujunzi Decoction,and so on)and active constituents(berberine,curcumin,and so on)can systematically ameliorate lipid metabolic disturbances by inhibiting SREBP-1c/2 activation and the expression of downstream genes such as FAS,ACC,and HMGCR.This review summarized clinical trials and experimental research in recent years on the mechanisms by which TCM prevents and treats HLP by regulating the SREBP pathway,aiming to provide theoretical basis and new insights for the prevention and treatment of HLP as well as further research.关键词
高脂血症/SREBP通路/中医药/研究进展Key words
hyperlipidemia/SREBP pathway/TCM/research advance引用本文复制引用
马润菡,王新陆,武瑞鹏,刘砚泽,申奥,平静涛,朱明军,王永霞..中医药调控SREBP通路防治高脂血症研究进展[J].中国中药杂志,2026,51(14):3939-3946,8.基金项目
国家科技重大专项(2024ZD0522001) （2024ZD0522001）
国家自然科学基金面上项目(82575022) （82575022）
河南省科技研发计划联合基金重点项目(242301420017) （242301420017）
河南省卫生健康委员会国家中医药传承创新中心联合共建科研专项(2024ZXZX1005) （2024ZXZX1005）
